Colgate-Palmolive Aktie News

Colgate-Palmolive (CL)'s diverse category system creates a deeper moat than its simple products suggest. It shows how shared chemistry, manufacturing flexibility and retail presence strengthen its competitive position. Hill's provides a stabilising demand pattern that supports the broader portfolio especially during slowdowns.

For investors, it's generally wise to buy and hold companies that continually raise their dividends. There are deals in energy, healthcare, consumer staples, and even the tech space.

Colgate-Palmolive (CL) is a Dividend King with a 62-year record of dividend growth and global dominance in oral care products. CL recently rebounded from a multi-year earnings decline, driven by its 2022 Global Productivity Initiative and renewed focus on growth businesses. Technical analysis shows institutional accumulation, with positive momentum signals and a breakout above resistance on str...

The decline in consumer staples stocks shows the disconnect between the consumer economy and stock market performance. Dividend Kings are excellent choices for investors who prioritize dividend reliability, and these five may appeal to value investors.

NEW YORK--(BUSINESS WIRE)--Colgate-Palmolive (NYSE:CL) Chief Growth Officer, John Hazlin and Chief Financial Officer, Stan Sutula, will participate in a fireside chat at the Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 2, 2025 at 9:30 a.m. ET. Investors may access a live webcast of this fireside chat on Colgate's website at www.colgatepalmolive.com.  For those unable ...

Bloomberg's 2025 Dividend Focus list highlights 36 dividend payers, with 16 qualifying as 'safer' due to free cash flow yields exceeding dividend yields. Top ten dividend stocks, including OZK, SLB, WM, and SUBCY, are projected to offer 12.5%-26.5% net gains by November 2026 based on analyst targets. Five 'IDEAL' stocks—CHHQF, VODAF, SUBCY, ITVPY, AVIFY—offer dividends from $1,000 invested that...

Colgate has been a solid defensive stock, rising 352% since 2000 while boosting its dividend. Despite this, it has narrowly trailed the S&P 500's return over that time frame.

AbbVie continues to enjoy strong growth from its new blockbuster drugs, Rinvoq and Skyrizi. Colgate-Palmolive is a rock-solid dividend growth stock simply out of fashion amid the tech craze.